Τίτλος:
Hypereosinophilic Syndrome as a Rare Cause of Reversible Biventricular Heart Failure
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Hypereosinophilic syndrome is a rare entity that can develop secondary to overproduction of eosinophilopoietic cytokines or as idiopathic disease. Cardiac involvement, which occurs often, is divided into 3 stages, the latter of which is nonreversible and leads to severe heart failure. Early detection and treatment of the syndrome is essential. For this reason, genetic testing for the FIP1L1-PDGFRA fusion gene has recently been added to the diagnostic algorithm. Patients with this mutation are at increased risk for the development of cardiac involvement and typically respond to treatment with the tyrosine kinase inhibitor imatinib mesylate. © 2017 Canadian Cardiovascular Society
Συγγραφείς:
Bonou, M.
Kapelios, C.J.
Benetos, G.
Moyssakis, I.
Giannakopoulou, N.
Diamantopoulos, P.
Korkolopoulou, P.
Variami, E.
Barbetseas, J.
Περιοδικό:
Canadian Journal of Cardiology
Εκδότης:
Pulsus Group Inc.
Λέξεις-κλειδιά:
brain natriuretic peptide; creatine kinase; imatinib; lactate dehydrogenase; prednisone; troponin; warfarin; anticoagulant agent; antineoplastic agent; cleavage and polyadenylation specificity factor; FIP1L1-PDGFRA fusion protein, human; imatinib; oncoprotein; platelet derived growth factor alpha receptor; prednisone; warfarin, adult; anemia; Article; case report; crackle; drug megadose; dyspnea; edema; embolism; fatigue; FIP1L1 PDGFRa gene; fusion gene; heart failure; heart left ventricle; heart left ventricle ejection fraction; heart murmur; heart muscle fibrosis; human; hypereosinophilic syndrome; intracardiac thrombosis; leukocyte count; lung congestion; male; mitral valve regurgitation; speckle tracking echocardiography; splenic embolism; splenomegaly; three dimensional echocardiography; thrombocytopenia; transthoracic echocardiography; two dimensional echocardiography; bone marrow examination; complication; echocardiography; genetics; heart failure; hypereosinophilic syndrome; mutation; pathophysiology; procedures; thrombosis; treatment outcome, Adult; Anticoagulants; Antineoplastic Agents; Bone Marrow Examination; Echocardiography; Heart Failure; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Prednisone; Receptor, Platelet-Derived Growth Factor alpha; Thrombosis; Treatment Outcome; Warfarin
DOI:
10.1016/j.cjca.2017.01.006
